<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03674827</url>
  </required_header>
  <id_info>
    <org_study_id>C3621001</org_study_id>
    <secondary_id>VBIR-2</secondary_id>
    <nct_id>NCT03674827</nct_id>
  </id_info>
  <brief_title>Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC</brief_title>
  <official_title>A PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ESCALATING DOSES AND TREATMENT INTENSIFICATION OF A VACCINE-BASED IMMUNOTHERAPY REGIMEN-2 (VBIR-2) (PF-06936308) FOR ADVANCED NON-SMALL CELL LUNG CANCER AND METASTATIC TRIPLE-NEGATIVE BREAST CANCER</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Part 1of the study will evaluate the safety, pharmacokinetics, pharmacodynamics and&#xD;
      immunogenicity of increasing doses of a vaccine-based immunotherapy regimen (VBIR-2) for&#xD;
      patients with advanced or metastatic non-small cell lung cancer and metastatic&#xD;
      triple-negative breast cancer.&#xD;
&#xD;
      Part 2 will evaluate the safety, pharmacokinetics and pharmacodynamics, immunogenicity and&#xD;
      preliminary evidence of efficacy of the Expansion dose of VBIR-2 in participants with&#xD;
      advanced or metastatic non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is divided into two parts, Dose Escalation (Part 1) in participants with NSCLC and&#xD;
      TNBC without acceptable alternative treatment options, followed by Dose Expansion (Part 2) in&#xD;
      participants with NSCLC who have progressed on or after treatment with platinum-based&#xD;
      chemotherapy and treatment with 1 immune checkpoint inhibitor, given concurrently or&#xD;
      sequentially with chemotherapy.&#xD;
&#xD;
      Part 1 has been completed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 27, 2018</start_date>
  <completion_date type="Actual">September 27, 2021</completion_date>
  <primary_completion_date type="Actual">September 27, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate Clinical Benefit Rate (CBR)</measure>
    <time_frame>Participant will have CT scans/MRI every 8 weeks until disease progression for up to 3 years to measure change from baseline</time_frame>
    <description>Proportion of participants who achieve complete response, partial response or stable disease for more than 6 months at 12, 24 and 36 months using RECIST 1.1. criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and grade of treatment-emergent adverse events including DLTs</measure>
    <time_frame>Baseline up to Day 29 in Cycle 1 (each cycle is 4 months)</time_frame>
    <description>DLTs in order to determine the maximum tolerated dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tremelimumab and sasanlimab single dose PK parameter (Cmax)</measure>
    <time_frame>Pre-dose on Day 1, Day 3-6, Day 8, Day 15, Day 22, Day 29, Day 57, Day 85 of Cycle 1 (each cycle is 4 months); pre-dose on Day 1 and Day 29 on Cycle 2; every 5 months thereafter up to Month 22; every 6 months thereafter up to 3 years</time_frame>
    <description>Maximum observed plasma concentration of tremelimumab and sasanlimab (Cmax).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tremelimumab and sasanlimab single dose PK parameter (Tmax)</measure>
    <time_frame>Pre-dose on Day 1, Day 3-6, Day 8, Day 15, Day 22, Day 29, Day 57, Day 85 of Cycle 1 (each cycle is 4 months); pre-dose on Day 1 and Day 29 on Cycle 2; every 5 months thereafter up to Month 22; every 6 months thereafter up to 3 years</time_frame>
    <description>Time to maximum concentration of tremelimumab and sasanlimab (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tremelimumab and sasanlimab single dose PK parameter AUC</measure>
    <time_frame>Pre-dose on Day 1, Day 3-6, Day 8, Day 15, Day 22, Day 29, Day 57, Day 85 of Cycle 1 (each cycle is 4 months); pre-dose on Day 1 and Day 29 on Cycle 2; every 5 months thereafter up to Month 22; every 6 months thereafter up to 3 years</time_frame>
    <description>Area under the curve from time zero extrapolated to infinity of tremelimumab and sasanlimab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tremelimumab and sasanlimab after multiple doses PK parameter (Ctrough)</measure>
    <time_frame>Pre-dose on Day 1, Day 3-6, Day 8, Day 15, Day 22, Day 29, Day 57, Day 85 of Cycle 1 (each cycle is 4 months); pre-dose on Day 1 and Day 29 on Cycle 2; every 5 months thereafter up to Month 22; every 6 months thereafter up to 3 years</time_frame>
    <description>Trough concentration after multiple doses of tremelimumab and sasanlimab (Ctrough)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti drug antibody (ADA) response of tremelimumab and sasanlimab after SC administration with the other components.</measure>
    <time_frame>Day 1, Day 29 and Day 85 on Cycle 1 (each cycle is 4 months); Day 29 on Cycle 2, every 4 months thereafter up to Month 22; every 6 months thereafter up to 3 years</time_frame>
    <description>Incidence and titers of anti-drug antibodies against tremelimumab and sasanlimab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate using RECIST 1.1</measure>
    <time_frame>Participant will have CT scans/MRI at baseline and every 8 weeks until disease progression for up to 3 years</time_frame>
    <description>Proportion of participants who achieve complete response or partial response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response using RECIST 1.1</measure>
    <time_frame>Participant will have CT scans/MRI at baseline and every 8 weeks until disease progression for up to 3 years</time_frame>
    <description>Median time from first response (complete or partial) until disease progression for up to 3 years in responders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival using RECIST 1.1</measure>
    <time_frame>Participant will have CT scans/MRI at baseline and every 8 weeks until disease progression for up to 3 years</time_frame>
    <description>Kaplan-Meier curve for progression up to 3 years.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <condition>Triple-negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Dose escalation (Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with NSCLC or TNBC were enrolled at escalating dose levels s of the VBIR-2 regimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion (Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with metastatic NSCLC will be enrolled at the expansion dose level identified during Part 1 of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-06936308</intervention_name>
    <description>PF-06936308 components will be administered 4 times per cycle. A cycle is 4 months.</description>
    <arm_group_label>Dose escalation (Part 1)</arm_group_label>
    <other_name>Vaccine-based immunotherapy regimen-2 (VBIR-2)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-06936308</intervention_name>
    <description>PF-06936308 components will be administered 4 times per cycle. A cycle is 4 months.</description>
    <arm_group_label>Dose Expansion (Part 2)</arm_group_label>
    <other_name>Vaccine-based immunotherapy regimen-2 (VBIR-2)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Part 1:Histological or cytological diagnosis of non-small cell lung cancer or&#xD;
        triple-negative breast cancer. Adequate bone marrow, renal and liver function.&#xD;
&#xD;
        Part 2: Histological or cytological diagnosis of metastatic non-small cell lung cancer&#xD;
        previously treated with 1 or 2 regimens in metastatic setting including a CPI and&#xD;
        platinum-based chemotherapy. Adequate bone marrow, renal and liver function.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known symptomatic brain metastases&#xD;
&#xD;
          -  ECOG performance status greater than or equal to 2&#xD;
&#xD;
          -  Concurrent immunotherapy&#xD;
&#xD;
          -  History of or active autoimmune disorders (including but not limited to: myasthenia&#xD;
             gravis, thyroiditis, pneumonitis, rheumatoid arthritis, multiple sclerosis, systemic&#xD;
             lupus, erythematosus, scleroderma) and other conditions that disorganize or alter the&#xD;
             immune system.&#xD;
&#xD;
          -  History of inflammatory bowel disease.&#xD;
&#xD;
          -  Current use of any implanted electronic stimulation device, such as cardiac demand&#xD;
             pacemakers, automatic implantable cardiac defibrillator, nerve stimulators, or deep&#xD;
             brain stimulators.&#xD;
&#xD;
          -  Presence of any surgical or traumatic metal implants at the site of administration&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSD Medical Center - Encinitas</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037-0845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Hospital)</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC San Diego Perlman Medical Offices</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ronald Reagan UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Hematology/Oncology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC San Diego Medical Center - Hillcrest</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Hematology/Oncology - Parkside</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Hematology/Oncology - Santa Monica</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD Medical Center - Vista</name>
      <address>
        <city>Vista</city>
        <state>California</state>
        <zip>92081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute, Inc.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Chicago Medical Center, CCD - Investigational Drug Service Pharmacy</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center at Silver Cross Hospital</name>
      <address>
        <city>New Lenox</city>
        <state>Illinois</state>
        <zip>60451</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orland Park - University of Chicago Center for Advanced Care</name>
      <address>
        <city>Orland Park</city>
        <state>Illinois</state>
        <zip>60462</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Horizon Oncology Research, LLC</name>
      <address>
        <city>Lafayette</city>
        <state>Indiana</state>
        <zip>47905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Kansas Cancer Center, Investigational Drug Services</name>
      <address>
        <city>Fairway</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Kansas Clinical Research Center</name>
      <address>
        <city>Fairway</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Kansas Cancer Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute Downtown</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute Pharmacy</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute, Norton Healthcare Pavilion</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norton Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center - West County</name>
      <address>
        <city>Creve Coeur</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barnes-Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University Infusion Center Pharmacy</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center - South County</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63129</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center - St. Peters</name>
      <address>
        <city>Saint Peters</city>
        <state>Missouri</state>
        <zip>63376</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah, Huntsman Cancer Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah, Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center - Translational Research Unit (TRU)</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=C3621001</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 29, 2018</study_first_submitted>
  <study_first_submitted_qc>September 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2018</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Immunologic Factors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

